Public Release: 

Breaking the backbone of triple-negative breast cancers

Rockefeller University Press

Putting the brakes on an abundant growth-promoting protein causes breast tumors to regress, according to a study published on March 19th in the Journal of Experimental Medicine.

Triple-negative breast tumors lack all of the known growth receptors that serve as treatment targets in other types of breast cancer, making this the most clinically challenging subtype of the disease. Patients with these tumors tend to relapse earlier and have shorter disease-free survival.

Andrei Goga and colleagues now show that triple-negative breast tumors express elevated levels of the growth-driving protein called MYC. MYC activity was required for the growth of these aggressive tumors, and blocking a MYC-cooperating protein, CDK, caused triple-negative tumors to shrink in mice.

Together, these results identify a potential new target for triple-negative tumor treatment.

###

About the Journal of Experimental Medicine

The Journal of Experimental Medicine (JEM) is published by The Rockefeller University Press. All editorial decisions on manuscripts submitted are made by active scientists in conjunction with our in-house scientific editors. JEM content is posted to PubMed Central, where it is available to the public for free six months after publication. Authors retain copyright of their published works and third parties may reuse the content for non-commercial purposes under a creative commons license. For more information, please visit www.jem.org.

Horiuchi, D., et al. 2012. J. Exp. Med. doi:10.1084/jem.20111512

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.